Movement Alert｜Tempus AI Intraday Rise 5.9% in Regular Trading, Strong Earnings Expectations and EU Certification Support Sentiment

Market Focus10-28 21:52

On October 28, Tempus AI rose 5.9% in Regular Trading, trading at $76.395 per share, with turnover of $68.184 million.

The move was accompanied by continued optimism ahead of the company’s November 2 earnings release and by recent EU Class C certification for its xR solid tumor RNA sequencing assay.

Market expectations point to quarterly revenue growth of 24.53%, with diagnostics revenue estimated at $289 million, or 75.65% of total revenue, while losses are expected to narrow from the prior period. Separately, the new EU certification under the In Vitro Diagnostic Regulation supports continued access for the xR assay in Europe beyond 2028 and also broadens its use in biopharma clinical studies, reinforcing the company’s commercial and regulatory positioning.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment